Ranasinghage Samaratunga, PhD, CRE
UC Physicians

Department Directory Profilearrow

  • Ranasinghage Samaratunga, PhD, CRE
  • Volunteer Assistant Professor Medical Physicist and Certified Radiation Expert
  •  
  • The University Hospital
  • (513) 584-6259
  • Samararc@Healthall.com

Education

  • BS, 1972, Colombo, Sri Lanka, University of Ceylon

Post Graduate Training/Education

  • Doctorate of Philosophy-1985, Boston University, Boston, Massachusetts

Credentials

  • Diplomate, American Board of Radiology, 1996, Diagnostic Radiologic Physics
  • Certified Radiation Expert in Diagnostic and Mammography, Ohio 096, 1998

Professional Affiliation

  • 2009, The University Hospital QA Committee for Radiation Generating Equipment, University Hospital, Cincinnati, OH
  • 1989-2005, University of Cincinnati Radiation Safety Committee, University of Cincinnati, Cincinnati, OH
  • -2001University of Cincinnati Dissertation Committee, University of Cincinnati, Cincinnati, OH
  • -1999University of Cincinnati Dissertation Committee, University of Cincinnati, Cincinnati, OH

Peer-reviewed Publications (in chronological order):

  • (Publications selected from 27 peer-reviewed publications)
  • Thomas SR, Stabin MG, Chen CT, & Samaratunga RC (1999). A dynamic urinary bladder model for radiation dose calculations.. Journal of Nuclear Medicine , 40(4), 102S-103S.
  • Maxon HR, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D, Moulton JS, Cummings D, Ehrhardt GJ, & Morris V (1998). Rhenium-188(Sn)HEDP for treatment of osseous metastases. Journal of Nuclear Medicine , 39(4), 659-63.
  • Maxon HR, Thomas SR, & Samaratunga RC (1997). Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid, 7(2), 183-7.
  • Pratt RG, Zheng J, Stewart BK, Shiferaw Y, McGoron AJ, Samaratunga RC, & Thomas SR (1997). Application of a 3D volume 19F MR imaging protocol for mapping oxygen tension (pO2) in perfluorocarbons at low field. Magnetic Resonance in Medicine , 37(2), 307-13.
  • Thomas SR, Pratt RG, Millard RW, Samaratunga RC, Shiferaw Y, McGoron AJ, & Tan KK (1996). In vivo PO2 imaging in the porcine model with perfluorocarbon F-19 NMR at low field. Magnetic Resonance Imaging , 14(1), 103-14.
  • Samaratunga RC, Thomas SR, Hinnefeld JD, Von Kuster LC, Hyams DM, Moulton JS, Sperling MI, & Maxon HR (1995). A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. Journal of Nuclear Medicine , 36(2), 336-50.
  • Thomas SR, Pratt RG, Millard RW, Samaratunga RC, Shiferaw Y, Clark LC, & Hoffmann RE (1994). Evaluation of the influence of the aqueous phase bioconstituent environment on the F-19 T1 of perfluorocarbon blood substitute emulsions. Journal of Magnetic Resonance Imaging , 4(4), 631-5.
  • RC, Pratt RG, Zhu Y, Massoth RJ, & Thomas SR (1994). Implementation of a modified birdcage resonator for 19F/1H MRI at low fields (0.14 T). Medical Physics , 21(5), 697-705.
  • Thomas SR, Millard RW, Pratt RG, Shiferaw Y, & Samaratunga RC (1994). Quantitative pO2 imaging in vivo with perfluorocarbon F-19 NMR: tracking oxygen from the airway through the blood to organ tissues. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology , 22(4), 1029-42.
  • Thomas SR, Samaratunga RC, Sperling M, & Maxon HR (1993). Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nuclear Medicine and Biology , 20(2), 157-62.
  • Thomas SR, Stabin MG, Chen CT, & Samaratunga RC (1992). MIRD Pamphlet No. 14: a dynamic urinary bladder model for radiation dose calculations. Journal of Nuclear Medicine , 33(5), 783-802.
  • Maxon HR, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, Scher HI, Moulton JS, Deutsch EA, & Deutsch KF (1992). Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Seminars in Nuclear Medicine , 22(1), 33-40.
  • Pratt RG, Thomas SR, Millard RW, Samaratunga RC, & Naseem MH (1992). Quantitation of perfluorocarbon blood substitutes in tissues using F-19 magnetic resonance spectroscopy. Biomaterials, Artificial Cells, and Immobilization Biotechnology , 20(2-4), 921-4.
  • Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga RC, Smith H, Moulton JS, Williams CC, & Ehrhardt GJ (1991). Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Journal of Nuclear Medicine , 32(10), 1877-81.
  • Norman AB, Bertram KJ, Thomas SR, Pratt RG, Samaratunga RC, & Sanberg PR (1991). Magnetic resonance imaging of rat brain following in vivo disruption of the cerebral vasculature. Brain Research Bulletin , 26(4), 593-7.
  • Sundararaman S, Denman D L, Legorreta R A, Foster A E, Redmond K P, Elson H R, Born A M, Samaratunga R C, Lewis G C, & Kereiakes J G (1990). The modification of specific absorption rates in interstitial microwave hyperthermia via tissue-equivalent material bolus. International Journal of Radiation Oncology, Biology, Physics , 19(3), 677-85.
  • Norman AB, Thomas SR, Pratt RG, Samaratunga RC, & Sanberg PR (1990). T1 and T2 weighted magnetic resonance imaging of excitotoxin lesions and neural transplants in rat brain in vivo. Experimental Neurology , 109(2), 164-70.
Copyright Information © 2009 University of Cincinnati | 234 Goodman St., Cincinnati, OH 45267 | (513) 584-4396